BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30861114)

  • 1. Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting.
    Landy R; Schiffman M; Sasieni PD; Cheung LC; Katki HA; Rydzak G; Wentzensen N; Poitras NE; Lorey T; Kinney WK; Castle PE
    Int J Cancer; 2020 Feb; 146(3):617-626. PubMed ID: 30861114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
    Befano B; Wentzensen N; Lorey T; Poitras N; Cheung LC; Schiffman M; Clarke MA; Cohen C; Kinney W; Locke A; Castle PE
    Gynecol Oncol; 2024 May; 184():89-95. PubMed ID: 38301311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting.
    Austin RM; Onisko A; Zhao C
    Am J Clin Pathol; 2018 Oct; 150(5):385-392. PubMed ID: 30137189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
    Silver MI; Schiffman M; Fetterman B; Poitras NE; Gage JC; Wentzensen N; Lorey T; Kinney WK; Castle PE
    Cancer; 2016 Dec; 122(23):3682-3686. PubMed ID: 27657992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
    Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
    Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
    Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
    Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
    Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
    J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.
    Orumaa M; Leinonen MK; Campbell S; Møller B; Myklebust TÅ; Nygård M
    Int J Cancer; 2019 Nov; 145(10):2629-2638. PubMed ID: 30734284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
    Hammer A; Demarco M; Campos N; Befano B; Gravitt PE; Cheung L; Lorey TS; Poitras N; Kinney W; Wentzensen N; Castle PE; Schiffman M
    Int J Cancer; 2020 Sep; 147(6):1612-1620. PubMed ID: 32141607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why does cervical cancer occur in a state-of-the-art screening program?
    Castle PE; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Schiffman M
    Gynecol Oncol; 2017 Sep; 146(3):546-553. PubMed ID: 28606721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.
    Gage JC; Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Behrens C; Sharma A; Zhao FH; Cuzick J; Yang ZH; Kinney WK
    Cancer Cytopathol; 2014 Nov; 122(11):842-50. PubMed ID: 25045058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of HPV testing in opportunistic cervical screening: Support for primary HPV screening in the United States.
    Cuzick J; Adcock R; Kinney W; Castle PE; Robertson M; McDonald RM; Stoler MH; Du R; Wheeler CM;
    Int J Cancer; 2023 Jul; 153(1):83-93. PubMed ID: 36946690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
    Gage JC; Schiffman M; Katki HA; Castle PE; Fetterman B; Wentzensen N; Poitras NE; Lorey T; Cheung LC; Kinney WK
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25038467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
    Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
    JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
    Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
    Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
    Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.
    Castle PE; Kinney WK; Xue X; Cheung LC; Gage JC; Zhao FH; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Katki HA; Schiffman M
    Ann Intern Med; 2018 Jan; 168(1):20-29. PubMed ID: 29181509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.